Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Karl Tapales/Getty Images

The Food and Drug Administration Wednesday approved Xofluza, the first novel treatment approved for the flu in almost 20 years, which targets the virus at an earlier stage in its development in the human body in the hopes of lessening recovery time.

Why it matters: Seasonal flu varies year-to-year but can be quite deadly, as seen last season when at least 80,ooo Americans were killed. Having another tool to combat the virus is "causing a lot of excitement in the public health community," says Mark Eisner, vice president of product development immunology, infectious disease and ophthalmology at Genentech, which made the drug.

The background: There was a lot of buzz when the Japanese company Shionogi announced that its drug was effective in killing off the virus in just 1 dose. It was further developed and commercialized globally with the Roche Group (including Genentech).

  • The FDA gave it priority review to expedite the approval process.
  • 2 clinical trials proved Xofluza is safe and effective, and that it facilitates a faster recovery compared to a placebo in a time roughly equal to patients taking another type of antiviral, Tamiflu (generic name oseltamivir).
  • Xofluza is now approved for acute flu patients 12 years of age and older who have been symptomatic for 48 hours or less.
  • "We're very happy FDA approved it before the flu season really started ... given how bad last year was," Eisner says.

Compared to Tamiflu, Xofluza requires 1 dose versus Tamiflu's 10 doses over 5 days.

  • Both treatments aim to halt flu replication in the human body but target different parts of its cycle. Xofluza blocks an enzyme needed for the virus to replicate earlier in the cycle and Tamiflu halts the replicated virus from leaving its host cell.
  • Both types drugs help multiple Type A and B strains of the virus.

What's next: Eisner says the drug has entered or is entering other trials to test in people younger than 12 years old, in patients hospitalized with severe flu already, whether it could prevent the transmission of flu and if it could be used as a post-exposure prophylactic.

Meanwhile, Anthony Fauci, head of the National Institute of Allergy and Infectious Disease, told Axios last week that everyone over 6 months of age should get vaccinated by the end of October.

  • So far, he said, "at this point, what we are seeing circulating around is a match to the vaccine" but even if that changes when the flu virus evolves, it will offer some protection.
  • While the Centers for Disease Control and Prevention says nationwide there is "low flu activity" as of the week ending October 14 , one child has died this 2018–2019 season.

Go deeper:

Go deeper

Obama says Powell exemplified what America "can and should be"

Then-President Obama speaks alongside former Secretary of State Colin Powell during a meeting in the Oval Office in 2010. Photo: Saul Loeb/AFP via Getty Images

Former President Obama called Colin Powell an "exemplary soldier and an exemplary patriot" in a statement honoring the former general following his death from COVID-19 complications on Monday.

Why it matters: Powell, the first Black U.S. secretary of state, was known as a Republican but played a critical role in helping Obama get elected in 2008.

Justice Department asks Supreme Court to block Texas abortion ban

Abortion rights activists rally at the Texas State Capitol on Sept. 11 in Austin, Texas. Photo: Jordan Vonderhaar/Getty Images

The Justice Department on Monday asked the Supreme Court to temporarily block Texas' near-total ban on abortions while federal courts consider its constitutionality.

The big picture: The court last month allowed the ban to take effect, rejecting an emergency application by abortion-rights groups. The law bars the procedure after cardiac activity is detected, as early as six weeks into pregnancy.

Updated 4 hours ago - Health

This arthritis drug cost $198 in 2008. Now it's more than $10,000

Illustration: Aïda Amer/Axios

In 2008, a box of 30 anti-inflammatory rectal suppositories that treats arthritis, called Indocin, had a price tag of $198. As of Oct. 1, the price of that same box was 52 times higher, totaling $10,350.

Why it matters: As federal lawmakers continue to waver on drug price reforms, Indocin is another example of how nothing prevents drug companies from hiking prices at will and selling them within a broken supply chain.